Indian Pharmaceutical Supplier to France.
France is one of the largest pharmaceutical markets in Europe and, through AP-HP, hosts the continent's largest hospital grouping by bed count. Regulated by the Agence nationale de sécurité du médicament et des produits de santé (ANSM) within the EU regulatory framework, priced through a structured CEPS negotiation informed by HAS clinical-benefit assessment, and procured through hospital groupings like UniHA and Groupements Hospitaliers de Territoire (GHT), France is a serious but demanding destination for Indian pharmaceutical supply. It requires EU-GMP certification on the manufacturing site, QP release inside the EU/EEA, French-language labelling, FMD serialisation and, for reimbursed supply, coherent CEPS pricing work. Hospital demand anchors on AP-HP, UniHA, Hospices Civils de Lyon, AP-HM Marseille and the CHU network across Bordeaux, Toulouse, Lille, Strasbourg and Rennes. Products enter through Paris Charles de Gaulle (CDG) and Marseille-Provence (MRS) for air, Le Havre and Marseille-Fos for sea. Our Mumbai regulatory desk coordinates ANSM and EU-procedure filings; our London commercial desk handles day-to-day EU coordination, QP partners and hospital-tender timing.
ANSM, EMA and the EU framework: serious infrastructure, serious expectations.
Supplying France is a full EU exercise. Products are authorised under the Centralised Procedure via the EMA for specific category lists (biotech, rare diseases, oncology, new-active-substance), under the Decentralised or Mutual Recognition Procedures for most generics and hybrids with France as a Concerned or Reference Member State, or through a purely national ANSM authorisation where the product does not touch other Member States. Each route carries its own dossier requirements (eCTD), inspection regime (EU-GMP, often verified through joint EMA/ANSM or EDQM inspections) and timelines (210-day review excluding clock stops for DCP/MRP).
For an Indian manufacturing site, the baseline is EU-GMP certification from a European inspectorate. ANSM, EDQM or any EU Member State's inspectorate can perform the qualifying inspection; the resulting certificate populates the EUDRA-GMP database and is the evidence used downstream by wholesalers, hospitals and QP sites. API supply is typically anchored on a Certificate of Suitability (CEP) from EDQM, which is the cleanest pathway for API acceptance in an EU dossier. Active Substance Master Files (ASMF) are accepted where a CEP is not practical.
QP release is mandatory and non-trivial. Every batch entering EU commerce must be certified by a Qualified Person based in an EU or EEA Member State, on the basis of batch-documentation review against the marketing authorisation and EU-GMP. QP release for Indian-sourced product can be performed in France (at a French wholesale-distributor or contract QP site) or at any other EU QP site with the appropriate licences. We coordinate QP release through established EU partner sites and build the QP chain into every supply plan from the first order.
Pricing and reimbursement for retail medicines runs through HAS clinical-benefit assessment (Service Médical Rendu, Amélioration du Service Médical Rendu) and CEPS price negotiation, with the generic pricing framework anchored to a mandatory discount against the reference brand price. Hospital-only products are negotiated through AP-HP, UniHA, Groupements Hospitaliers de Territoire and individual CHU procurement separately from retail reimbursement. FMD serialisation with 2D Data Matrix barcode at pack level and anti-tampering device on secondary packaging is mandatory on every pack placed on the French market.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capabilities, shaped around EU regulatory rigour.
EU procedure dossier preparation
eCTD dossiers for DCP, MRP or purely national ANSM authorisation, with France as RMS or CMS where the launch plan justifies it. Coordination with EDQM on CEP maintenance, ASMF on API disclosure where needed, and the full EU Module 1 including RCP and notice patient in French.
EU-GMP inspection support
Preparation and coordination for ANSM, EDQM or Member State inspectorate audits of Indian manufacturing sites: site master file updates, CAPA tracking, audit-day logistics, post-inspection response and EUDRA-GMP database lifecycle management.
QP release coordination
Batch-documentation packages for EU QP release: batch manufacturing records, analytical certificates, deviation and change-control evidence, aligned to the marketing authorisation and EU-GMP. QP release performed through established EU partner sites with France-licensed wholesale onward distribution.
AP-HP and UniHA tender response
Technical and commercial pack tuned to AP-HP and UniHA tender formats: AMM number, CEP or ASMF reference, EU QP site, French-language artwork, FMD serialisation evidence, CEPS or hospital price anchor and delivery-schedule discipline.
CEPS pricing and HAS coordination
Where a reimbursed retail launch is in scope, HAS dossier preparation for SMR/ASMR evaluation and CEPS negotiation support, anchored to realistic reference-brand pricing and the generic discount framework. Hospital pricing runs separately through the tender track.
French-language artwork and FMD serialisation
ANSM-compliant French artwork with native-speaker medical review, RCP and notice patient translation, outer-carton layout to EU conventions, 2D Data Matrix serialisation integrated to EMVS, and anti-tampering device on secondary packaging.
Mumbai to Paris CDG, Marseille for Mediterranean routing.
Air freight: BOM-CDG runs direct on Air France in about nine hours flight time, and via the Gulf on Emirates, Qatar Airways or Etihad with block times of ten to eleven hours including transfer. Paris Charles de Gaulle (CDG) handles the majority of pharmaceutical air cargo into France through dedicated pharma-handling zones at the cargo terminals, with CEIV Pharma-certified ground handling agents. Marseille-Provence (MRS) covers Mediterranean-oriented supply and southern-France direct distribution. Door-to-door for ambient pharmaceutical cargo clears in three to five working days; EU customs clearance works through the EU single-window framework with our nominated customs-broker at CDG or MRS.
Sea freight: Nhava Sheva to Le Havre or Marseille-Fos runs a twenty-to-twenty-eight-day transit, with weekly sailings from MSC, CMA CGM, Maersk and Hapag-Lloyd. Le Havre handles the bulk of northern-France pharmaceutical sea cargo with onward Seine-valley and Paris-region distribution; Marseille-Fos covers Mediterranean and southern-France routing. Less-than-container-load consolidation is available for orders below 10 CBM. Ambient-only by sea; all 2-8 and 15-25 temperature-controlled pharmaceutical volume moves by air.
Cold-chain: Envirotainer RAP e2 and RKN e1 for 2-8 degrees active, va-Q-tec passive for 15-25 ambient, and continuous temperature logging on every consignment. CDG's CEIV Pharma infrastructure is among the most developed in Europe; the airport's pharma zone provides dedicated cool-dolly, hold-over refrigerated storage and temperature-controlled last-mile pickup. We default to direct Air France rotations for 2-8 product where capacity allows. Insurance on Institute Cargo Clauses A, door-to-door, with EU-specific clauses where the credit-insurer line requires it.
Payment terms: hospital-tender terms are set by the grouping (AP-HP, UniHA), typically 60 to 90 days against delivery. Wholesale-distributor and private supply terms: TT 30% advance and 70% against scanned Bill of Lading for first-time customers, or sight LC through BNP Paribas, Crédit Agricole, Société Générale or HSBC France. Repeat customers move to open account at 60 to 90 days subject to credit-insurer cover (Atradius, Euler Hermes, Coface are all active in France).
What AP-HP, UniHA and the CHU network actually order.
Hospital-only injectables are the core category for Indian supply into France. AP-HP and UniHA tender large volumes on broad-spectrum antibiotics (piperacillin-tazobactam, meropenem, vancomycin, linezolid, ceftazidime), critical-care injectables (noradrenaline, vasopressin, propofol, rocuronium, midazolam), anaesthesia and peri-operative lines, large-volume parenterals and standard hospital injectable formulary. Oncology therapeutic injectables (biosimilar trastuzumab, rituximab, bevacizumab, pegfilgrastim; capecitabine; gemcitabine; carboplatin; cisplatin) are a rising category, with hospital biosimilar uptake in France among the highest in Europe driven by explicit AP-HP and UniHA procurement preferences.
Retail generics through French wholesale distributors (OCP, CERP Rouen, Alliance Healthcare France) cover the full primary-care formulary: cardiometabolic (statins, ARBs, beta-blockers, metformin, SGLT2 inhibitors, long-acting insulin analogues), antibiotics, analgesics, gastrointestinal lines, respiratory and women's-health products. The generic pricing framework constrains retail economics tightly; EU-GMP sourcing discipline and FMD-compliant serialisation are non-negotiable.
Every line ships with ANSM-compliant French artwork, FMD-serialised packs, EU QP release documentation and CoA-per-batch traceability.
A European sponsor used M Care through 2023 and 2024 as Indian-side manufacturing partner on a four-SKU hospital-injectable biosimilar and critical-care bundle. Indian sites already held EU-GMP certification and CEPs on the relevant APIs; we coordinated the eCTD pack for a DCP with France as Reference Member State, supported EDQM CEP maintenance, and built the EU QP-release chain through an established French partner. Marketing authorisations issued inside the 210-day clock plus expected clock stops. First AP-HP supply landed through CDG on an Air France CEIV-Pharma routing three weeks after QP release, with UniHA tender entry following in the next procurement cycle. FMD serialisation and 2D-barcode integration at pack level ran clean from batch one.
Why Indian pharma, why M Care, and what a French buyer actually receives.
France is a demanding market and also a rewarding one. AP-HP and UniHA buy at industrial scale, the hospital biosimilar uptake environment is one of Europe's more progressive, and the generic retail market is large enough to carry multiple Indian suppliers per molecule. What France does not tolerate is corner-cutting on EU-GMP, QP release, French labelling or FMD serialisation. An Indian supplier that arrives with a clean European inspection history, CEPs on the relevant APIs and a real EU QP chain is taken seriously immediately; one that arrives without is invisible.
M Care's Mumbai head office handles the dossier and CMC engine: eCTD preparation, EDQM CEP coordination, ASMF where it applies, EU-GMP inspection support, site master file discipline, stability and analytical data packages. Our London commercial desk handles EU-side coordination: QP partner arrangements, French hospital-tender timing, CEPS pricing work where a reimbursed launch is in scope, French wholesale-distributor relationships and the day-to-day regulatory-lifecycle management after AMM. This split matters because French supply is a constant-operational-discipline exercise rather than a one-time regulatory event: FMD serialisation, batch QP release, pharmacovigilance reporting and tender renewal all need the EU-side presence.
Three specifics make the relationship different. First, realistic scoping at the first brief. We do not tell a sponsor that France is straightforward when the site has not yet completed EU-GMP certification; we tell them what the path is and what it costs in time and capital. Second, CEP-first API posture where the molecule supports it, because CEP holders clear EU dossier hurdles substantially faster than ASMF-only supply. Third, disciplined tender delivery. AP-HP and UniHA award multi-year contracts with fixed delivery schedules; missing a quarter because of capacity planning error is not a minor issue, and we scope capacity commitments against real manufacturing allocation rather than aspirational.
One practical note for first-time French buyers: the hospital-tender and the reimbursed-retail pathways are two different commercial games and require different pricing logic. We structure the initial brief so the sponsor is clear whether AP-HP and UniHA is the primary target (in which case pricing reference is recent tender award history, not CEPS) or whether retail reimbursement is the primary target (in which case the CEPS and HAS workstreams are the load-bearing piece of the plan).
France pharmaceutical import: common questions.
Which authority regulates pharmaceuticals in France?
The Agence nationale de sécurité du médicament et des produits de santé (ANSM), operating within the EU framework. Products can be authorised centrally through EMA, via DCP or MRP with France as CMS or RMS, or through a purely national ANSM authorisation.
Does the Indian manufacturing site need EU-GMP?
Yes. A valid EU-GMP certificate from an EU Member State inspectorate, EDQM or EMA-coordinated inspection is a prerequisite. The certificate populates the EUDRA-GMP database and is the evidence used downstream by wholesalers, hospitals and QP sites.
How does QP release work?
Every batch entering EU commerce must be QP-released by a Qualified Person in the EU/EEA, on the basis of batch-documentation review against the marketing authorisation and EU-GMP. QP release can be performed in France or at any EU QP site with the appropriate licences; we coordinate the QP chain through established partners.
Is French-language labelling mandatory?
Yes. French outer-carton, Résumé des Caractéristiques du Produit (RCP) and notice patient are mandatory, reviewed and approved by ANSM. FMD serialisation with 2D Data Matrix and anti-tampering device on secondary packaging is also mandatory.
How is pricing determined?
Reimbursed retail pricing runs through HAS clinical-benefit assessment and CEPS price negotiation, with the generic pricing framework anchored to a mandatory discount against the reference brand. Hospital-only products are negotiated through AP-HP, UniHA and GHT groupings separately from retail reimbursement.
What cold-chain routes do you use into France?
BOM-CDG direct on Air France and via the Gulf hubs (DXB, DOH, AUH), with Envirotainer or va-Q-tec containers and continuous temperature logging. CDG's CEIV Pharma infrastructure supports dedicated cool-dolly and refrigerated hold-over. Le Havre and Marseille-Fos for ambient sea-freight volume. Insurance on Institute Cargo Clauses A, door-to-door.
How is payment typically structured?
Hospital-tender terms are set by the grouping, typically 60 to 90 days against delivery. Wholesale and private-sector first-time: TT 30/70 or sight LC through BNP Paribas, Crédit Agricole, Société Générale or HSBC France. Repeat customers move to open account at 60 to 90 days subject to credit-insurer cover (Atradius, Euler Hermes, Coface).
Why buyers choose M Care for the India → France corridor.
ANSM fluency
Dossiers built to the exact format ANSM reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → CDG direct air for time-critical orders, and Le Havre for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in France.
Top categories we ship to France
Anti-infectives
Penicillins, cephalosporins, carbapenems, antivirals, antimalarials — 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
Oncology
Cytotoxics, targeted therapy and supportive care — bortezomib, docetaxel, paclitaxel, gemcitabine.
Diabetes & endocrine
Insulins, oral antidiabetics, thyroid and hormonal therapy — 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals — 1,283 SKUs, our broadest catalogue.
Molecule, volume, target buyer. One working day to a quote.
Your enquiry goes directly to the account manager responsible for France. No call-centre hops, no generic autoresponders, just the answer your procurement file needs.
Start a France enquiry → Back to all markets